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Abstract
Bovine respiratory disease complex is the most economically significant disease of feedlot cattle. Putative
causal organisms include Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and
Mycoplasma bovis, bovine herpesvirus, bovine viral diarrhea virus, bovine respiratory syncytial virus, and
parainfluenza type 3 virus. Although vaccination against the putative causal organisms is a frequently used
approach to aid in the prevention of BRD, it is also common and legal for antibiotics to be used for
metaphylaxis at the arrival of beef cattle at feedlots. With a more significant concern for prudent antibiotic use
in the beef industry, it is essential for decision making with regards BRDC management to understand the
efficacy of metaphylaxis as a preventive management practice for BRDC. Systematic reviews of randomized
controlled trials yield the highest level of evidence for the efficacy of treatment under field conditions, and
comparative efficacy can be examined using network meta-analysis for multiple comparisons. Establishing the
efficacy of metaphylaxis for the prevention of BRDC will serve to improve decision makers’ ability to engage
in effective stewardship of antibiotics.
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PRISMA-P ITEM 1 Title  
What is the efficacy of metaphylaxis using antibiotics for the prevention of Bovine Respiratory Disease in 
beef cattle? 
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This protocol is archived in the Iowa State University institutional repository and published online with 
Systematic Reviews for Animals and Food (SYREAF) available at: http://www.syreaf.org/. The 
systematic review will be reported using the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement guidelines [1, 2]. This protocol is reporting using the items (headings) 
recommended in the PRISMA-P guidelines [3, 4]. 
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1 Introduction.  
PRISMA-P ITEM 6 Rational:  
Bovine respiratory disease complex is the most economically significant disease of feedlot cattle.  Putative 
causal organisms include Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and 
Mycoplasma bovis, bovine herpesvirus, bovine viral diarrhea virus, bovine respiratory syncytial virus, and 
parainfluenza type 3 virus. Although vaccination against the putative causal organisms is a frequently used 
approach to aid in the prevention of BRD, it is also common and legal for antibiotics to be used for 
metaphylaxis at the arrival of beef cattle at feedlots. With a more significant concern for prudent antibiotic 
use in the beef industry, it is essential for decision making with regards BRDC management to understand 
the efficacy of metaphylaxis as a preventive management practice for BRDC. Systematic reviews of 
randomized controlled trials yield the highest level of evidence for the efficacy of treatment under field 
conditions, and comparative efficacy can be examined using network meta-analysis for multiple 
comparisons. Establishing the efficacy of metaphylaxis for the prevention of BRDC will serve to improve 
decision makers’ ability to engage in effective stewardship of antibiotics. 
PRISMA-P ITEM 7 Objectives:   
The objective of this protocol is to describe a systematic review to address the efficacy of metaphylaxis 
with antibiotics for the prevention of BRDC in feedlot cattle. The specific review questions to be addressed 
in this protocol are as follows: 
What is the efficacy of metaphylaxis using antibiotics for the prevention of Bovine Respiratory Disease in 
beef cattle? The specific PICO elements, which will define the eligibility criteria, are as follows: 
x Population: Weaned cattle raised for meat in intensive systems at risk of BRDC, i.e., feedlot cattle. 
Calves explicitly described as veal or dairy calves are excluded from consideration. 
x Intervention: Parentally metaphylactic use of antibiotics at the feedlot with 48 hours of arrival. 
Metaphylactic use is defined as “medicating a group of animals to prevent the occurrence of disease 
when a disease outbreak is expected”. We consider the distinction between prophylactic and 
metaphylactic uses to be of mainly of academic interest. We are interested in approaches to 
medicating animals before they show clinical signs of BRD when it expected that are at risk of 
BRD. 
x Comparator: No antibiotics at arrival or an alternative antibiotics metaphylaxis. 
x Outcomes:  Critical outcomes will be the cumulative incidence of first-treatment for BRDC in the 
first 45 days of the feedlot period. Secondary outcomes will be the cumulative incidence of first-
treatment rate BRDC in the entire feedlot period and BRDC mortality in the entire feed period. 
2 Methods 
PRISMA-P ITEM 8 Eligibility criteria:   
In addition to eligibility criteria as described in the PICO elements described above, eligibility criteria will 
include publication in English. Both published and unpublished (grey literature) studies are eligible, 
provided they report a primary research study with a concurrent comparison group using an eligible study 
design. Eligible designs will be trials with a concurrent control group conducted in feedlot settings, i.e., 
groups of penned cattle receiving rations rather than grazing on pasture.  Studies must describe a trial where 
the investigator selected the allocation. Cluster–randomized controlled trials (C-RCT) or individually –
randomized controlled trials (I-RCT) are eligible, although we anticipate all will be C-RCT.   
PRISMA-P ITEM 9 Information sources:   
We will conduct the literature search in a range of relevant bibliographic databases and other information 
sources containing both published and unpublished literature. Table 1 presents the resources to be searched.  
Table 1: Databases and information sources to be searched 
Database / information source Interface / URL 
MEDLINE®, MEDLINE In-Process and MEDLINE®  Daily Epub 
Ahead of Print 
Ovid SP  
CAB Abstracts  (via Web of 
Science)  
Science Citation Index  (via Web of 
Science)  
Conference Proceedings Citation Index – Science (via Web of 
Science)  
Agricola Proquest 
We will also hand-search the table of contents of the following relevant conferences from 1997 to 2018: 
x Proceedings of the American Association of Bovine Practitioners; 
x World Association for Buiatrics; 
x USDA FDA FOI requests for antibiotics registered for metaphylaxis use in the USA 
We will also check the reference lists of any included studies for any eligible studies that may have been 
missed by the database searches. 
PRISMA-P ITEM 10 Search strategy:  
A Science Citation Index (Web of Science) search strategy designed to identify studies on the efficacy of 
metaphylaxis using antibiotics for the prevention of BRD in beef cattle is presented in Table 2 
The search strategy employs three concepts:  
• Beef cattle   
AND  
• BRD 
AND 
Metaphylaxis 
Table 2:Search strategy to identify studies the efficacy of metaphylaxis using 
antibiotics for the prevention of BRD in beef cattle in Science Citation Index (Web 
of Science) 
 
# 10 #9 AND #2 AND #1 338  
# 9 #8 OR #7 OR #6 OR #5 OR #4 OR #3 291,929  
# 8 TS=((arrival* OR arrive* OR "arriving" OR "entry" OR enter*) NEAR/5 
(medicat* OR antimicrobial* OR "anti-microbial*" OR antibiotic* OR 
"anti-biotic*" OR antibacterial* OR "anti-bacterial*" OR antiinfect* OR 
"anti-infect*" OR bacteriocid* OR bactericid* OR microbicid* OR "anti-
mycobacteri*" OR antimycobacteri* OR "amoxicillin" OR "amoxycillin" 
OR "ampicillin" OR "erythromycin" OR "ceftiofur" OR "cloxacillin" OR 
"danofloxacin" OR "enrofloxacin" OR "florfenicol" OR "gentamycin" OR 
"gentamicin" OR "lincomycin" OR "oxytetracycline" OR "penicillin" OR 
"spectinomycin" OR "sulfamethoxazole" OR "tilmicosin" OR 
"trimethoprim" OR "tulathromycin" OR "tylosin" OR "gamithromycin" 
OR "tildipirosin")) 
8,411 
# 7 TS=(("mass" OR "blanket" OR prevent*) NEAR/5 ("amoxicillin" OR 
"amoxycillin" OR "ampicillin" OR "erythromycin" OR "ceftiofur" OR 
"cloxacillin" OR "danofloxacin" OR "enrofloxacin" OR "florfenicol" OR 
"gentamycin" OR "gentamicin" OR "lincomycin" OR "oxytetracycline" OR 
"penicillin" OR "spectinomycin" OR "sulfamethoxazole" OR "tilmicosin" 
OR "trimethoprim" OR "tulathromycin" OR "tylosin" OR 
"gamithromycin" OR "tildipirosin")) 
1,241 
# 6 TS=(("mass" OR "blanket") NEAR/5 (medicat* OR "dosing" OR 
"administration")) 
3,091 
# 5 TS=(("population wide" OR "whole population*") NEAR/5 (treatment* 
OR therap* OR antimicrobial* OR "anti-microbial*" OR antibiotic* OR 
"anti-biotic*" OR antibacterial* OR "anti-bacterial*" OR antiinfect* OR 
anti-infect* OR bacteriocid* OR bactericid* OR microbicid* OR "anti-
mycobacteri*" OR antimycobacteri*)) 
106 
# 4 TS=(("mass" OR "blanket" OR prevent*) NEAR/5 (treatment* OR 
therap* OR antimicrobial* OR "anti-microbial*" OR antibiotic* OR "anti-
biotic*" OR antibacterial* OR "anti-bacterial*" OR antiinfect* OR anti-
infect* OR bacteriocid* OR bactericid* OR microbicid* OR "anti-
mycobacteri*" OR antimycobacteri*)) 
148,469 
# 3 TS=(prophyla* OR metaphyla* OR "meta-phyla*") 141,094 
# 2 TS=("respiratory disease*" OR "respiratory tract disease*" OR "respiratory 
virus*" OR "respiratory tract virus*" OR "shipping fever" OR 
"undifferentiated fever" OR "BRD" OR "BRDC" OR "pasteurellosis" OR 
"pasteurella multocida" OR "p multocida" OR "mycoplasma" OR 
pneumonia* OR pleuropneumonia* OR "pneumonitis" OR 
"pneumonitides") 
217,568 
# 1 TS=("cow" OR "cows" OR "cattle" OR heifer* OR "steer" OR "steers" 
OR "bull" OR "bulls" OR "calf" OR "calves" OR "youngstock*" OR 
"young-stock*" OR "beef" OR "veal" OR "bovine" OR "bovinae" OR 
buiatric*) 
524,340 
 
The search strategies will not be limited by date, language, or publication type. We will conduct searches 
using each database listed in the protocol, translating the agreed strategy appropriately to reflect the 
differences in database interfaces and functionality.   
We will document all search strategies and search results, and we will provide this in the final report to 
meet standard requirements for clear and formal reporting of the search process. We will conduct the 
literature search in a range of relevant bibliographic databases and other information sources containing 
both published and unpublished literature.  
PRISMA-P ITEM 11 Study records: 
 Data management:  We will download the results of searches in a tagged format and load them into 
bibliographic software (EndNote). The results will be deduplicated using several algorithms and the 
duplicate references held in a separate EndNote database for checking if required. We will save results from 
resources that do not allow export in a format compatible with EndNote in Word or Excel documents as 
appropriate and manually de-duplicate. The de-duplicated search results from EndNote will be uploaded 
into online systematic review software (DistillerSR®, Ottawa, ON, Canada). Reviewers will have training 
in epidemiology and systematic review methods. Before both abstract and full-text screenings, data 
extraction, and risk-of-bias assessment, the reviewers assigned to each step will undergo training to ensure 
consistent data collection using the forms created in DistillerSR®.  
Selection process:  In the first round of screening, abstracts and titles will be screened for inclusion. Two 
reviewers will independently evaluate each citation for relevance using the following questions: 
1) Does the study involve assessment of a metaphylaxtic use of antibiotics for the prevention/control of 
bovine respiratory disease in feedlot cattle?  
x Yes/Unclear- next question 
x No –exclude 
2) Is there a concurrent comparison group? (i.e., controlled trial with natural or deliberate disease exposure 
or analytical observational study)? 
x Yes/Unclear- include for full-text assessment 
x No –exclude 
Citations will be excluded if both reviewers respond “no” to any of the questions. If one reviewer says "yes", 
the citation will move to full-text assessment. A pre-test will be conducted by all reviewers on the first 100 
abstracts to ensure clarity of questions and consistency of understanding of the questions. Following 
title/abstract screening, eligibility will be assessed through full-text screening. The same questions will be 
used as for the title / abstract screening for citations with the full-text available in English. Two reviewers 
will independently evaluate the full-text articles, with any disagreements resolved by consensus. If 
consensus cannot be reached, a third reviewer will be consulted. 
1) Correct population: Is the study population, weaned cattle in a non-grazing situation that are at risk of 
developing BRDC naturally, i.e., feedlot cattle?  
x Yes- next question 
x No –exclude 
2) Correct Interventions and Comparator: Does the study assess the use of antibiotics, at a registered dose 
for metaphylaxis for prevention/control of BRDC in feedlot cattle?  
x Yes- next question 
x No –exclude 
3) Correct outcome: Does the study report the risk of BRDC in the study groups? 
x Yes- next question -  
x No- exclude 
4) Correct study design: Is the study a field trial, where an investigator is allocating animals to the 
intervention group- randomized or non-randomized? 
x Yes- include in data extraction  
x No –challenge study (indicate the antibiotic(s) studied)  
x No - observational study (the investigator did not allocate to the group – allocation was 
chosen by producers or owner)  
Data collection process: Data will be extracted by two reviewers working independently. Consensus will 
resolve any disagreements or, if consensus cannot be reached, a third reviewer will be consulted.  Authors 
will not be contacted to request missing data or to clarify published results. A form for data extraction will 
be created for this review in DistillerSR® and pre-tested on 4 full-text articles to ensure question clarity. 
PRISMA-P ITEM 12 Data items:   
Study-level data collected: 
x Country 
x Location 
x Year of conduct 
x Breed 
x Age (entire group or control group data if provided) 
x Weight (entire group or control group data if provided) 
x Definition of BRDC 
x No of animals eligible for the study 
x Unit of allocation (Cluster (pen) or individual)  
x Approach to allocation 
x The endpoint for cumulative incidence estimate  
Arm-level data collected: 
x Antibiotic label dose regime –As with the prior review, data will be aggregated between treatment 
arms within a trial if the difference between those treatment arms was due to a difference in the 
post-metaphylactic interval or route of antimicrobial administration or a comparison of doses on 
the same label  
x  
x  Trade name as reported by investigators  
x The timing of administration compared to the arrival 
x Number of animals enrolled 
x Number of animals lost to follow up 
x Number of animals analyzed 
x Number of clusters for C-RCT 
x For C-RCT, the approach to the analysis of non-independent observations i.e., not reported, 
"multilevel model", a "variance components analysis" or may use "generalized estimating 
equations" (GEEs), among other techniques. 
For non-randomized studies, the only information extracted will be the antibiotic label dose regime and 
trade names used for the study. This information will be most useful when deciding what, if any important , 
studies had been conducted using a non-randomized trial.  
 
PRISMA-P ITEM 13 Outcomes and prioritization:   
For the primary outcome of interest, the risk of BRDC in the first 45 days. When multiple dates are available, 
we will select the one closest to 28 days. We will extract the possible metrics for BRDC risk in the following 
order.  
For C-RCT and I-RCT (few/non expected) 
x 1st priority: Adjusted summary effect size (adjusted risk ratio or adjusted odds ratio), variables included 
in adjustment, precision estimate and variance components estimates. 
x 2nd priority: Unadjusted summary effect size and corresponding precision estimate  
x 3rd priority: Arm-level risk of BRDC 
Prioritization means we will not collected the additional metrics if the prioritized metric is reported. The 
rationale for the prioritzation is that the meta-analysis should use an adjusted summary effect, as most 
relevant (all) studies are cluster randomized trials, and therefore the other metrics will require conversion 
to the summary effect.    
The secondary outcomes are first-treatment rate of BRDC in the entire feedlot period and second-treatment 
rate for BRDC, and we will prioritize the same metrics. 
PRISMA-P ITEM 14 Risk of bias in individual studies:   
Risk of bias will be assessed for controlled trials with natural disease exposure. Risk-of-bias assessment 
will be performed at the outcome level for each of the critical outcomes using the Cochrane risk of bias 
instrument (Higgins et al., 2016), with the signaling questions modified as necessary for the specific review 
question. The ROB 2.0 for clustered –RCTs and individual RCTs will be used depending upon the study 
design [5]. These tools are available at https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool. 
PRISMA-P ITEM 15 Data synthesis:  
Network meta-analysis. Network meta-analysis (aka mixed treatment comparison meta-analysis) will use 
the approach described by NICE Decision Support Unit technical document [6-9]. The approach to 
reporting will use the PRISMA- NMA (http://www.prisma-
statement.org/Extensions/NetworkMetaAnalysis.aspx). For cluster-randomized trials, it will be necessary 
to verify that the potential for a unit-of-analysis error did not bias the estimate of precision. When the unit 
of analysis was not adjusted, we will use the approach previously proposed to adjust for non-independent 
observations [10].  If network meta-anlaysis can not be preformed, we will conduct pairwise meta-analyses. 
PRISMA-P ITEM 16 Meta-bias(es):  
 Small-study effects (“publication bias”) will be assessed using funnel plots for all vaccine-comparator 
combinations where there are at least ten studies in the meta-analysis. If feasible, we will use approaches 
to assessing publication bias in the network of evidence using previously proposed approaches [11, 12].  
PRISMA-P ITEM 17 Confidence in cumulative evidence:   
The quality of evidence for each critical outcome will be assessed using the approach proposed by GRADE 
[13, 14], while also considering the nature of the network meta-analysis [15, 16].   
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